Circumvention of multi-drug resistance of cancer cells by Chinese herbal medicines

Chinese Medicine

Volumn 5, Issue , 2010, Pages

  Chai, Stella ^a   To, Kenneth K W ^a   Lin, Ge ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; BERBAMINE; BERBAMINE DERIVATIVE; BREAST CANCER RESISTANCE PROTEIN; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FRITILLARIA THUNBERGII EXTRACT; GINSENOSIDE; GINSENOSIDE RB 1; GINSENOSIDE RB 2; GINSENOSIDE RC; GINSENOSIDE RD; GINSENOSIDE RE; GINSENOSIDE RG 1; GINSENOSIDE RG 3; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; HOMOHARRINGTONINE; MATRINE; MULTIDRUG RESISTANCE PROTEIN 1; PEIMINE; PLANT EXTRACT; TETRAMETHYLPYRAZINE; TETRANDRINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; VINBLASTINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER CELL; CANCER RESISTANCE; CHINESE HERB; CHINESE MEDICINE; DRUG ACCUMULATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG UPTAKE; EFFUSION; FRITILLARIA; FRITILLARIA THUNBERGII; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; REVIEW;

EID: 77954813506     PISSN: None     EISSN: 17498546     Source Type: Journal    
DOI: 10.1186/1749-8546-5-26     Document Type: Review

References (120)

1. Meszaros A, Balogh G. Multiple Drug Resistance 2009, Lancaster, UK: Gazelle Distribution.
2. Biedler JL, Riehm H. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res 1970, 30:1174-1184.
3. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002, 53:615-617. 10.1146/annurev.med.53.082901.103929, 11818492.
4. La Porta CAM. Drug resistance in melanoma: new perspectives. Curr Med Chem 2007, 14(4):387-91. 10.2174/092986707779941078, 17305541.
5. Watson JV. Introduction to Flow Cytometry 1991, Cambridge: Cambridge University Press.
6. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006, 5(3):219-234. 10.1038/nrd1984, 16518375.
7. Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist 2003, 8(5):411-424. 10.1634/theoncologist.8-5-411, 14530494.
8. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta - Biomembranes 1976, 455(1):152-162.
9. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 1990, 38(9):1277-1287.
10. Thiebaut F, Tsuruo T, Hamada H, Gotteman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987, 84(21):7735-7738. 10.1073/pnas.84.21.7735, 299375, 2444983.
11. Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, Harrell PM, Trinh YT, Zhang Q, Urbatsch IL, Chang G. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 2009, 323(5922):1718-1722. 10.1126/science.1168750, 2720052, 19325113.
12. Shapiro AB, Ling V. Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur J Biochem 1997, 250(1):130-137. 10.1111/j.1432-1033.1997.00130.x, 9432000.
13. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992, 258(5088):1650-1654. 10.1126/science.1360704, 1360704.
14. Dean M, Hamon Y, Chimini G. The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 2001, 42(7):1007-1017.
15. Liu F. Mechanisms of chemotherapeutic drug resistance in cancer therapy--a quick review. Taiwan J Obstet Gynecol 2009, 48(3):239-244. 10.1016/S1028-4559(09)60296-5, 19797012.
16. Roelofsen H, Vos TA, Schippers IJ, Kuipers F, Koning H, Moshage H, Jansen PLM, Müller M. Increased levels of the multidrug resistance protein in lateral membranes of proliferating hepatocyte-derived cells. Gastroenterology 1997, 112(2):511-521. 10.1053/gast.1997.v112.pm9024305, 9024305.
17. Kruh GD, Gaughan KT, Godwin A, Chan A. Expression pattern of MRP in human tissues and adult solid tumor cell lines. J Natl Cancer Inst 1995, 87(16):1256-1258. 10.1093/jnci/87.16.1256, 7563173.
18. Hipfner DR, Deeley RG, Cole SPC. Structural, mechanistic and clinical aspects of MRP1. Biochim Biophys Acta - Biomembranes 1999, 1461(2):359-376.
19. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998, 95(26):15665-15670. 10.1073/pnas.95.26.15665, 28101, 9861027.
20. Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 1998, 58(23):5337-5339.
21. Miyake K, Mickley L, Litman T, Zhan Z, Robey R, Cristensen B, Brangi M, Greenberger L, Dean M, Fojo T, Bates SE. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res 1999, 59(1):8-13.
22. Taylor EM. Efflux transporters and the blood-brain barrier 2005, New York: Nova Publishers.
23. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper RJ, Schellens JH. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001, 61(8):3458-3464.
24. Sarkadi B, Homolya L, Szakács G, Váradi A. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol Rev 2006, 86(4):1179-1236. 10.1152/physrev.00037.2005, 17015488.
25. Litman T, Druley TE, Stein WD, Bates SE. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 2001, 58(7):931-959. 10.1007/PL00000912, 11497241.
26. Twentyman PR. Cyclosporins as drug resistance modifiers. Biochem Pharmacol 1992, 43(1):109-117. 10.1016/0006-2952(92)90668-9, 1346494.
27. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981, 41(5):1967-1972.
28. Toppmeyer D, Seidman AD, Pollak M, Russell C, Tkaczuk K, Verma S, Overmoyer B, Garg V, Ette E, Harding MW, Demetri GD. Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. Clin Cancer Res 2002, 8(3):670-678.
29. Stewart A, Steiner J, Mellows G, Laguda B, Norris D, Bevan P. Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration. Clin Cancer Res 2000, 6(11):4186-4191.
30. Tian H, Pan QC. A comparative study on effect of two bisbenzylisoquinolines, tetrandrine and berbamine, on reversal of multidrug resistance. Yao Xue Xue Bao 1997, 32(4):245-250.
31. He QY, Meng FH, Zhang HQ. Reduction of doxorubicin resistance by tetrandrine and dauricine in harringtonine-resistant human leukemia (HL60) cells. Zhongguo Yao Li Xue Bao 1996, 17(2):179-181.
32. He QY, Jiang B, Zhang HQ, Xue SB. Reversal of doxorubicin resistance by tetrandrine in Chinese hamster ovary cell line. Zhongguo Yao Li Xue Bao 1992, 13(5):416-419.
33. Choi SU, Park SH, Kim KH, Choi EJ, Kim S, Park WK, Zhang YH, Kim HS, Jung NP, Lee CO. The bisbenzylisoquinoline alkaloids, tetrandine and fangchinoline, enhance the cytotoxicity of multidrug resistance-related drugs via modulation of P-glycoprotein. Anticancer Drugs 1998, 9(3):255-261. 10.1097/00001813-199803000-00008, 9625436.
34. Sun AX, Ye ZG, Li CY, Xue BY, Li LF, Cao XF, Yang Q, Dai BQ. Synergistic anticancer effects of tetrandrine combined with doxorubicin or vincristine in vitro. Acta Pharmacol Sin 1999, 20(1):69-73.
35. Li GH, Pan CY, Sun FJ, Wang XR, Yin GP. Reversal effect of 4 alkaloids on apoptosis of being obtained multi-drug resistance to tumour cell. Chin Trad Patent Medicine 2006, 28(7):1001-1004.
36. Fu LW, Zhang YM, Liang YJ, Yang XP, Pan QC. The multidrug resistance of tumour cells was reversed by tetrandrine in vitro and in xenografts derived from human breast adenocarcinoma MCF-7/adr cells. Eur J Cancer 2002, 38(3):418-426. 10.1016/S0959-8049(01)00356-2, 11818209.
37. Wang F, Wang L, Yang J, Nomura M, Miyamoto K. Reversal of P-glycoprotein-dependent resistance to vinblastine by newly synthesized bisbenzylisoquinoline alkaloids in mouse leukemia P388 cells. Biol Pharm Bull 2005, 28(10):1979-1982. 10.1248/bpb.28.1979, 16204959.
38. Xu WL, Shen HL, Ao ZF, Chen BA, Xia W, Gao F, Zhang YN. Combination of tetrandrine as a potential-reversing agent with daunorubicin, etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia. Leuk Res 2006, 30(4):407-413. 10.1016/j.leukres.2005.08.005, 16219352.
39. Ding YF, Xie X, Zhao JY, Yang PM. Reversal of adriamycin resistance by matrine in leukemia multidrug resistance cell line K562/ADM. J Dalian Med Univ 2004, 26(4):256-258, 279.
40. Li XF, Zhang SZ, Zheng S. Cellular biological effects of matrine on K562 and K562/Vin cells. Chin J Pathophysiol 2002, 18(10):1233-1237.
41. Tan Z. Neural protection by naturopathic compounds - an example of tetramethylpyrazine from retina to brain. J Ocul Biol Dis Infor 2009, 2(2):57-64. 10.1007/s12177-009-9024-8, 2723671,2723671, 19672463.
42. Yang L, Yang PD, Liang R, Yuan YC, Tian Q. Study on reversal of multidrug resistance in leukemia by tetramethylphylpyrazine combining with cyclosporin A. Chin J Cancer 2000, 19(4):304-306.
43. Zhou C, Shen P, Cheng Y. Quantitative study of the drug efflux kinetics from sensitive and MDR human breast cancer cells. Biochim Biophys Acta - Gen Subjects 2007, 1770(7):1011-1020.
44. Hao LH, Zhao JY, Yang PM. The Studies of Tetramethylpyrazine in Combination with β-Elemene on Induction of the Apoptosis and the Reversal of Multidrug Resistance in K562/ADM Cells Line. Chin J Clin Oncol 2005, 32(1):25-28, 33.
45. Ji YB, Ji CF, Zou X, Gao SY. Study on the effects of two kinds of cactus polysaccharide on erythrocyte membrane protein and fluidity of the lipid in S180 mice. Zhongguo Zhong Yao Za Zhi 2004, 29(10):967-970.
46. Li JH, Yang PM. Study on ligustrazine in reversing multidrug resistance of K562/ADM cell. Mod J Integr Chin Tradit West Med 2001, 10(15):1405-1407.
47. Li SL, Chan SW, Li P, Lin G, Zhou GH, Ren YJ, Chiu FC. Pre-column derivatization and gas chromatographic determination of alkaloids in bulbs of Fritillaria. J Chromatogr A 1999, 859(2):183-192. 10.1016/S0021-9673(99)00867-5, 10574211.
48. Lin G, Li SL, Li P, Chan SW. Chromatographic analysis of Fritillaria isosteroidal alkaloids, the active ingredients of Beimu, the antitussive traditional Chinese medicinal herb. J Chromatogr A 2001, 935(1-2):321-338. 10.1016/S0021-9673(01)01258-4, 11762784.
49. Hu HW, Zheng HX, Qi J, Hou L, Zuo MH, Chen XY, Sun YL, Xu YF, Shao XF, Yang CZ. Study of reversing multi-drug resistant by Peimine. Chin J Hem 1999, 20(12):650-651.
50. Dong Q, Zheng S, Xu R, Lu Q, He L. Study on effect of berbamine on multidrug resistance leukemia K562/Adr cells. Chin J Integr Tradit West Med 2004, 24(9):820-822.
51. Han Y, Yuan J, Shi Y, Zhu Y, Wu S. Reversal effect of berbamine on multidrug resistance of K562/DOX cells and its mechanism. J Exp Hematol 2003, 11(6):604-608.
52. Cheng YH, Qi J, Xiong DS, Liu JW, Qi SL, Pan B, Yang CZ, Zhu HF. Reversal of multidrug resistance in drug-resistant human breast cancer cell line MCF-7/ADR by calmodulin antagonist O-(4-ethoxyl-butyl)-berbamine. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2006, 28(2):164-168.
53. Kim SW, Kwon HY, Chi DW, Shim JH, Park JD, Lee YH, Pyo S, Rhee DK. Reversal of P-glycoprotein-mediated multidrug resistance by ginsenoside Rg3. Biochem Pharmacol 2003, 65(1):75-82. 10.1016/S0006-2952(02)01446-6, 12473381.
54. Park JD, Kim DS, Kwon HY, Son SK, Lee YH, Baek NI, Kim SI, Rhee DK. Effects of ginseng saponin on modulation of multidrug resistance. Arch Pharm Res 1996, 19(3):213-218.
55. Gao RL, Lin XJ, Qian XD, Chen XH, Niu YP. Effect of ginsenosides and panaxatriol extracted from ginseng on inhibition of proliferation, inducing apoptosis and cytotoxic drug sensitivity in leukemic cells. J Chin Med Res 2004, 4(2):97-99.
56. Wang L. Reversing drug resistance of human erythroleukemia cell line K562/DOX on DOX by total saponings Panax ginseng. J Chongqing Med Univ 2003, 28(4):424-427, 435.
57. Shi XK, Zhang YJ, Zhao CJ. The reverse effects of ginseng saponin Rb1 on multidrug resistance of human leukemic cell line K562/HHT in vitro. Acta Acad Med Militaris Tertiae 1999, 21(11):825-827.
58. Li Y, Wang ZZ, Yu TF. In vitro study on the reversal of multidrug resistance (MDR) in HL60/VCR cell line with ginsenoside - Rb1. J Radioimmunol 2005, 18(5):362-365.
59. Liu LL, Liu YE, Fang GT. Reversal effect of Panax notoginseng saponins on multidrug resistance breast cancer cell MCF/ADM. Lishizhen Med Materia Med Res 2008, 19(4):954-956.
60. Si YQ, Tien TD. The multidrug resistant reversing effect of total Panax notoginseng saponins studied in K562/VCR cell line. Chin J Tradit Med Sci Technol 2005, 12(5):292-294.
61. Kim SH, Yeo GS, Lim YS, Kang CD, Kim CM, Chung BS. Suppression of multidrug resistance via inhibition of heat shock factor by quercetin in MDR cells. Exp Mol Med 1998, 30(2):87-92.
62. Kioka N, Hosokawa N, Komano T, Hirayoshi K, Nagata K, Ueda K. Quercetin, a bioflavonoid, inhibits the increase of human multidrug resistance gene (MDR1) expression caused by arsenite. FEBS Lett 1992, 301(3):307-309. 10.1016/0014-5793(92)80263-G, 1349537.
63. Cai X, Chen FY, Han JY, Gu CH, Zhong H, Teng Y, Ouyang RR. Reversal of multidrug resistance of HL-60 adriamycin resistant leukemia cell line by quercetin and its mechanisms. Chin J Oncol 2005, 27(6):326-329.
64. Cai X, Chen FY, Han JY, Gu CH, Zhong H, Ouyang RR. Restorative effect of quercetin on subcellular distribution of daunorubicin in multidrug resistant leukemia cell lines K562/ADM and HL-60/ADM. Chin J Cancer 2004, 23(12):1611-1615.
65. Kothan S, Dechsupa S, Leger G, Moretti JL, Vergote J, Mankhetkorn S. Spontaneous mitochondrial membrane potential change during apoptotic induction by quercetin in K562 and K562/adr cells. Can J Physiol Pharm 2004, 82(12):1084-1090.
66. Limtrakul P, Khantamat O, Pintha K. Inhibition of P-glycoprotein function and expression by kaempferol and quercetin. J Chemother 2005, 17(1):86-95.
67. Wang Y, Chao PL, Hsiu SL, Wen K, Hou Y. Lethal quercetin-digoxin interaction in pigs. Life Sci 2004, 74(10):1191-1197. 10.1016/j.lfs.2003.06.044, 14697403.
68. Ganta S, Amiji M. Coadministration of paclitaxel and curcumin in nanoemulsion formulations To overcome multidrug resistance in tumor cells. Mol Pharm 2009, 6(3):928-939. 10.1021/mp800240j, 19278222.
69. Chang HY, Pan KL, Ma FC, Jiao XY, Zhu HF, Liu JH, Huang Y, Cao YH. The study on reversing mechanism of multidrug resistance of K562/DOX cell line by curcumin and erythromycin. Chin J Hem 2006, 27(4):254-258.
70. Tang XQ, Bi H, Feng JQ, Cao JG. Effect of curcumin on multidrug resistance in resistant human gastric carcinoma cell line SGC7901/VCR. Acta Pharmacol Sin 2005, 26(8):1009-1016. 10.1111/j.1745-7254.2005.00149.x, 16038636.
71. Ying HC, Zhang SL, Lv J. Drug-resistant reversing effect of curcumin on COC1/DDP and its mechanism. J Mod Oncol 2007, 15(5):604-607.
72. Um Y, Cho S, Woo HB, Kim YK, Kim H, Ham J, Kim SN, Ahn CM, Lee S. Synthesis of curcumin mimics with multidrug resistance reversal activities. Bioorg Med Chem 2008, 16(7):3608-3615. 10.1016/j.bmc.2008.02.012, 18295490.
73. Limtrakul P, Anuchapreeda S, Buddhasukh D. Modulation of human multidrug-resistance MDR-1 gene by natural curcuminoids. BMC Cancer 2004, 4:13. 10.1186/1471-2407-4-13, 404465, 15090070.
74. Limtrakul P, Chearwae W, Shukla S, Phisalphong C, Ambudkar SV. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. Mol Cell Biochem 2007, 296(1-2):85-95. 10.1007/s11010-006-9302-8, 16960658.
75. Piwocka K, Bielak-Mijewska A Sikora E. Curcumin induces caspase-3-independent apoptosis in human multidrug-resistant cells. Ann N Y Acad Sci 2002, 973:250-254. 10.1111/j.1749-6632.2002.tb04643.x, 12485871.
76. Anuchapreeda S, Thanarattanakorn P, Sittipreechacharn S, Tima S, Chanarat P, Limtrakul P. Inhibitory effect of curcumin on MDR1 gene expression in patient leukemic cells. Arch Pharm Res 2006, 29(10):866-873. 10.1007/BF02973907, 17121181.
77. Choi BH, Kim CG, Lim Y, Shin SY, Lee YH. Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt/NF kappa B pathway. Cancer Lett 2008, 259(1):111-118. 10.1016/j.canlet.2007.10.003, 18006147.
78. Huang M, Jin J, Sun H, Liu GT. Reversal of P-glycoprotein-mediated multidrug resistance of cancer cells by five schizandrins isolated from the Chinese herb Fructus Schizandrae. Cancer Chemother Pharmacol 2008, 62(6):1015-1026. 10.1007/s00280-008-0691-0, 18270702.
79. Slaninová I, Brezinová L, Koubíková L, Slanina J. Dibenzocyclooctadiene lignans overcome drug resistance in lung cancer cells--study of structure-activity relationship. Toxicol In Vitro 2009, 23(6):1047-1054. 10.1016/j.tiv.2009.06.008, 19531378.
80. Wan CK, Zhu GY, Shen XL, Chattopadhyay A, Dey S, Fong WF. Gomisin A alters substrate interaction and reverses P-glycoprotein-mediated multidrug resistance in HepG2-DR cells. Biochem Pharmacol 2006, 72(7):824-837. 10.1016/j.bcp.2006.06.036, 16889754.
81. Cao CM, Ding XD, Wang XH, Liu P. Clinical study of shengmai injection in its reversing MDR effect in late phase colon carcinoma patients. Shandong J Tradit Chin Med 2005, 24(9):529-532.
82. Lin SY, Qin ZQ, Xu YF, Wu LC, Liu LM. Significance of combination shenmal injection, tamoxifen and nifedipine in treatment stage IV non-small cell lung cancer. Chin J Cancer Prev Treat 2002, 9(4):454-455.
83. Wang J, Xia Y, Wang H, Hou Z. Chinese herbs of Shenghe powder reverse multidrug resistance of gastric carcinoma SGC-7901. Integr Cancer Ther 2007, 6(4):400-404. 10.1177/1534735407309765, 18048888.
84. Xu L, Wang MY, Xu DQ, Zhou CX. Experimental study on modified "Sanwubai Powder" in affecting multi-drug resistance gene expression of tumor. Shanghai J Tradit Chin Med 2005, 39(8):59-60.
85. Qu Y, Liu SQ, Zhang XB, Bai SH, Tang XY, Zhang TH, Liu BL. Reversal of P-glycoprotein mediated multidrug resistance by traditional Chinese medicines. Nat Prod Res Dev 2006, 18(6):932-936.
86. Yu LF, Wu YL, Zhang YP. Reversal of drug resistance in the vincristine-resistant human gastric cancer cell lines MKN28/VCR by emulsion of seminal oil of Brucea Javanica. World Chin J Digestol 2001, 9(4):376-378.
87. Tang T, Meng LH, Chen LJ, Ding J. Reversal of multidrug resistance and inhibition of DNA topoisomerase II by emulsion of seed oil of Brucea Javanica. Chin Pharmacol Bull 2001, 17(5):539-542.
88. Feng ZQ, Guo Y, Zhu NX, Lu QH, Shen MH, Wu LC, Wang ZS. The experiment of SANGENG mixture decoction on reversing multidrug resistance. Bull Chin Cancer 2003, 12(6):370-371.
89. Guo Y, Xie CS, Feng ZQ. The study of effects on accumulation and efflux of intracellular adrimycine with FFTLG for multidrug resistant cell lines K562/ADR and K562/VCR in vitro. Chin J Mod Appl Pharm 2002, 19(4):268-272.
90. Lin GF. Current situation in studying the reversing effect in multidrug-resistant in cancer cells by TCM. China Pharm 2007, 16(10):63-64.
91. Chen XY, Liu JT. Study on tumor cells' multidrug resistance and its reversion by Chinese herbs. J Chin Integr Med 2003, 1(3):221-225.
92. Li Q, Liu ZJ, Zhang J, Shi YJ, Gong JP. The effects of GanAi-1 on the reversal of multidrug resistance in hepcatocellular carcinoma. J Dig Surg 2006, 5(1):70-73.
93. Yang GW, Dang Q, Li XM. Reversal effects and mechanism study of Tianfoshen on drug resistance of human erythrocyte leukaemic cell strain K562/ADM. Mod J Integr Tradit Chin West Med 2002, 11(19):1865-1867.
94. Lu WP, Suen GZ. Effect of Zeng Xio umbilical plaster in MDR malignant ascites patient. J Chin Physician 2006, 34(2):48-50.
95. Ye ZG, Wang JH, Sun AX, Liang AH, Xue BY, Li CY, Wang L. Potentiation of vincristine-induced apoptosis by tetrandrine, neferine and dauricine in the human mammary MCF-7 multidrug-resistant cells. Yao Xue Xue Bao 2001, 36(2):96-99.
96. Li JH, Qin FQ, Yang PM. Reversal of multidrug resistance in human K562/ADM cell line by dauricine. J Dalian Med Univ 2002, 24(2):94-96.
97. Liu ZM, Xu ZP, Shou LH. Progress of reversing multi-drug resistant in TCM. Chin J Integr Trad West Med 1999, 19(12):757-759.
98. Tian F, Pan QC. Comparative study for reversing multi-drug resistant in dauricine and daurisoline. Chin J Cancer 1996, 15(6):410-414.
99. Song XR, Hou SX. Research progress in reversing multi-drug resistant in TCM. Zhongguo Zhong Yao Za Zhi 2005, 30(16):1300-1304.
100. Sun HJ, Wang XQ, Yu LM, Zhao JY, Yang PM. The study of paeonol for MDR's reverse action. Prog of Anat Sci 2000, 6(1):59-62.
101. Sun GP, Wang H, Shen YX, Zhai ZM, Wei W, Xu SY. Study on effects of paeonol in inhibiting growth of K562 and inducing its apoptosis. Chin Pharmacol Bull 2004, 20(5):550-552.
102. Dong QH, Zheng S, Lu QH. Study on the effect of Kanglaite injection on MDR human leukemia cell lines. J Pract Oncol 2002, 17(1):24-26.
103. Xia L, Shen P. Studies on the effects of Siwu Mixture on reversing multidrug resistance of human erythrocyte leukemic cell line K562/ADM. Zhongguo Zhong Yao Za Zhi 2004, 29(8):792-795.
104. Wong VK, Chiu P, Chung SS, Chow LM, Zhao YZ, Yang BB, Ko BC. Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo. Clin Cancer Res 2005, 11(16):6002-6011. 10.1158/1078-0432.CCR-05-0209, 16115945.
105. Chang JY, Chang CY, Kuo CC, Chen LT, Wein YS, Kuo YH. Salvinal, a novel microtubule inhibitor isolated from Salvia miltiorrhizae bunge (Danshen), with antimitotic activity in multidrug-sensitive and -resistant human tumor cells. Mol Pharmacol 2004, 65(1):77-84. 10.1124/mol.65.1.77, 14722239.
106. Efferth T, Davey M, Olbrich A, Rücker G, Gebhart E, Davey R. Activity of drugs from traditional Chinese medicine toward sensitive and MDR1-or MRP1-overexpressing multidrug-resistant human CCRF-CEM leukemia cells. Blood Cells Mol Dis 2002, 28(2):160-168. 10.1006/bcmd.2002.0492, 12064912.
107. Zhang HZ, Yang L, Ren LM, Liu SM. Drug screening for reversal of multidrug resistance in tumor cell from Chinese drug active compounds in vitro. J North China Coal Med Coll 2003, 5(3):265-267.
108. Li JW. Study progress in TCM for the multidrug-resistant reversing effect. Hebei J TCM 2007, 29(6):557-560.
109. Yang SL, Pang J, Chen HP. Research progress in reversing MDR by Chinese medicine. J Hepatobiliary Surg 2008, 16(6):477-479.
110. Chang XH, Xiang Y, Huang SL. Review on revering multidrug resistance with Chinese herbs leukemia. J Bran Camp First Mil Med Univ 2004, 27(2):200-203.
111. Bao WL. Study progress in MDR reversal effect in Chinese medicine. Lishizhen Med Mater Med Res 2008, 19(12):2905-2907.
112. Suen JL, Li CJ, Liang F, Liu JX. Thoughts in using TCM to reverse multidrug resistance. Chin Arch Trad Chin Med 2006, 24(4):736-737.
113. Liu LS, Tien JH, Shi ZM. Advances in research on reversing multidrug resistance of tumour. Trad Chin Med Res 2003, 16(1):43-45.
114. Ma Q, Zhang ZS. Research review in reversing MDR by TCM. J Hunan Coll TCM 2002, 22(4):70-72.
115. Sadava D, Still DW, Mudry RR, Kane SE. Effect of ganoderma on drug-sensitive and multidrug-resistant small-cell lung carcinoma cells. Cancer Lett 2009, 277(2):182-189. 10.1016/j.canlet.2008.12.009, 19188016.
116. Gu YL, Chu HH, Bu P. Experimental study for reversing MDR in gastric cancer by several TCM. Trad Chin Drug Res Clin Pharmacol 2007, 18(2):114-116.
117. Gu W, Zhai XF, Zhang YN, Ling CQ. In vitro study of Ganli injection on reversing acquired multidrug resistance of human hepatocellular carcinoma. Chin Trad Herbal Drugs 2007, 38(6):871-874.
118. Cao Y, Xia Q, Meng H, Zhong A. Pharmacological effects of serum containing chinese medicine bushen huayu jiedu compound recipe in lung cancer drug-resistance cells. Chin J Integr Med 2008, 14(1):46-50. 10.1007/s11655-007-9004-4, 18219453.
119. Cao Y, Zhang D, Zheng GJ, Yang Y, Zhang J. Study on drug resistance reversion and mechanism of bushen huayu jiedu formula in lung cancer cells of drug resistance. Shandong J Trad Chin Med 2004, 23(2):100-104.
120. Sadava D, Ahn J, Zhan M, Pang ML, Ding J, Kane SE. Effects of four Chinese herbal extracts on drug-sensitive and multidrug-resistant small-cell lung carcinoma cells. Cancer Chemother Pharmacol 2002, 49(4):261-266. 10.1007/s00280-002-0427-5, 11914903.